

in a continuing or divisional application. Claims 29, 37, 39 and 40 have been amended to more particularly point out and distinctly claim the subject matter of the present invention. Support for the amendments can be found throughout the specification. No new matter is added.

I. Rejection Under 35 U.S.C. § 102(b)

Claims 27-40 were rejected as unpatentable under 35 U.S.C. § 102(b) as allegedly anticipated by United States Patent No. 4,284,786 to Kämmerer et al. (Kämmerer). Applicants have canceled claims 27 and 28. Claim 29 has been amended to depend from claim 1. Each of claims 29-40, as amended, depends either directly or indirectly from claim 1. Claim 1 was allowed by the Examiner, thus Applicants respectfully submit that dependant claims 29-40 are allowable.

II. Rejection Under 35 U.S.C. § 102(e)

Claims 27-40 were rejected as unpatentable under 35 U.S.C. § 102(e) as allegedly anticipated by either United States Patent No. 6,303,792 to Lau et al. (Lau) or by United States Patent No. 6,221,891 to Faasch et al. (Faasch). Applicants have canceled claims 27 and 28. Claim 29 has been amended to depend from claim 1. Each of claims 29-40, as amended, depends either directly or indirectly from claim 1. Claim 1 was allowed by the Examiner, thus Applicants respectfully submit that dependant claims 29-40 are allowable.

CONCLUSION

In view of the foregoing amendments and remarks, Applicants respectfully submit that claims 1-26 and 29-40 are in condition for allowance. Early and favorable action by the Examiner is earnestly

solicited. If the Examiner believes that issues may be resolved by a telephone interview, the Examiner is urged to telephone the undersigned at the number below.

No fee beyond that due for the extension of time is believed due for the submission of this response. The Commissioner is authorized to charge any required fees that may be due to Deposit Account No.11-0600.

Respectfully submitted,

Date: May 20, 2003

By: 

Ian Scott

Reg. No. 44,327

KENYON & KENYON
One Broadway
New York, NY 10004

Tel: (212) 425-7200
Fax: (212) 425-5288

APPENDIX A

Marked-up Version of Amended Claims

29. (Amended) The leflunomide of claim [27] 1 which is substantially free of N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide.
37. (Amended) A pharmaceutical composition comprising the leflunomide of any of claims [27] 29 through 36.
39. (Amended) A method of treating rheumatoid arthritis comprising administering to a patient in need of such treatment a therapeutically effective amount of the leflunomide of any of claims [27] 29 through 36.
40. (Amended) A method of regulating cell proliferation comprising administering to a patient a an amount of the leflunomide of any of claims [27] 29 through 36 sufficient to inhibit cell proliferation.